Reviewing Shattuck Labs (STTK) & Its Rivals

Shattuck Labs (NASDAQ:STTK) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Shattuck Labs to related businesses based on the strength of its analyst recommendations, valuation, dividends, earnings, risk, profitability and institutional ownership.

Earnings and Valuation

This table compares Shattuck Labs and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Shattuck Labs	$1.00 million	-$48.81 million	-10.43
Shattuck Labs Competitors	$722.75 million	$12.98 million	-10.01

Shattuck Labs’ competitors have higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Shattuck Labs and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Shattuck Labs Competitors	-9,054.47%	-198.89%	-30.64%

Volatility & Risk

Shattuck Labs has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Shattuck Labs’ competitors have a beta of 1.11, indicating that their average stock price is 11% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Shattuck Labs and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1	0	9	3	3.08
Shattuck Labs Competitors	9774	15043	45272	1571	2.54

Shattuck Labs currently has a consensus target price of $13.70, indicating a potential upside of 157.52%. As a group, “Biotechnology” companies have a potential upside of 99.66%. Given Shattuck Labs’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Shattuck Labs is more favorable than its competitors.

Insider & Institutional Ownership

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 12.9% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Shattuck Labs beats its competitors on 7 of the 13 factors compared.

Shattuck Labs Company Profile

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.